MENU
+Compare
NTLA
Stock ticker: NASDAQ
AS OF
Nov 28 closing price
Price
$8.99
Change
+$0.47 (+5.52%)
Capitalization
1.04B

NTLA Intellia Therapeutics Forecast, Technical & Fundamental Analysis

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics... Show more

Industry: #Biotechnology
NTLA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for NTLA with price predictions
Nov 28, 2025

NTLA in upward trend: price may jump up because it broke its lower Bollinger Band on October 27, 2025

NTLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 38 cases where NTLA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NTLA's RSI Oscillator exited the oversold zone, of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where NTLA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 28, 2025. You may want to consider a long position or call options on NTLA as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NTLA just turned positive on November 25, 2025. Looking at past instances where NTLA's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

NTLA moved below its 50-day moving average on October 27, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on November 04, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NTLA entered a downward trend on November 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.391) is normal, around the industry mean (27.168). P/E Ratio (0.000) is within average values for comparable stocks, (52.496). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.897). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (16.393) is also within normal values, averaging (334.447).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NTLA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
NTLA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

NTLA is expected to report earnings to rise 5.49% to -97 cents per share on February 19

Intellia Therapeutics NTLA Stock Earnings Reports
Q4'25
Est.
$-0.97
Q3'25
Beat
by $0.09
Q2'25
Beat
by $0.05
Q1'25
Beat
by $0.17
Q4'24
Beat
by $0.07
The last earnings report on November 06 showed earnings per share of -92 cents, beating the estimate of -100 cents. With 3.71M shares outstanding, the current market capitalization sits at 1.04B.
A.I. Advisor
published General Information

General Information

a developer of proprietary, potentially curative therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
40 Erie Street
Phone
+1 857 285-6200
Employees
526
Web
https://www.intelliatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BAFHX18.880.17
+0.91%
Brown Advisory WMC Strat Eurp Eq Instl
JGINX82.900.43
+0.52%
Janus Henderson Growth And Income I
FSCIX36.750.12
+0.33%
Fidelity Advisor Small Cap I
FNKCX16.350.03
+0.18%
Frank Value C
RMBLX54.660.04
+0.07%
RMB Mendon Financial Services I

NTLA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+5.52%
VCYT - NTLA
69%
Closely correlated
-0.78%
BEAM - NTLA
60%
Loosely correlated
+1.20%
CRSP - NTLA
59%
Loosely correlated
+0.32%
AXON - NTLA
55%
Loosely correlated
+1.31%
EDIT - NTLA
49%
Loosely correlated
+0.42%
More